← All trials
NCT04908748
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Mar 1, 2022
- First posted
- Jun 1, 2021
- Last posted
- Jun 1, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Teikoku Seiyaku Co., Ltd.Lead sponsor
- ClinigenCollaborator
- ClinSearch, LLCCollaborator
- Teikoku Seiyaku Co., Ltd.Study chair
- CRM Biometrics GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.